Lifecore Biomedical Inc. (LFCR) - Cash Flow Conversion Efficiency

Latest as of February 2026: 0.226x

Based on the latest financial reports, Lifecore Biomedical Inc. (LFCR) has a cash flow conversion efficiency ratio of 0.226x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.70 Million) by net assets ($20.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Lifecore Biomedical Inc. (LFCR) balance sheet quality index to measure how much of total assets are equity-financed.

Lifecore Biomedical Inc. - Cash Flow Conversion Efficiency Trend (1996–2025)

This chart illustrates how Lifecore Biomedical Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Lifecore Biomedical Inc. cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Lifecore Biomedical Inc. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Lifecore Biomedical Inc. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Seshasayee Paper and Boards Limited
NSE:SESHAPAPER
-0.036x
Kafrit
TA:KAFR
0.104x
Bank Artha Graha Internasional
JK:INPC
0.010x
Black Spade Acquisition II Co Unit
NASDAQ:BSIIU
-0.002x
Associated Alcohols & Breweries Ltd.
NSE:ASALCBR
0.080x
InfuSystems Holdings Inc
NYSE MKT:INFU
0.017x
Elektrotim SA
WAR:ELT
0.047x
Astral Resources NL
AU:AAR
-0.011x

Annual Cash Flow Conversion Efficiency for Lifecore Biomedical Inc. (1996–2025)

The table below shows the annual cash flow conversion efficiency of Lifecore Biomedical Inc. from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Lifecore Biomedical Inc..

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-05-31 $1.34 Million $-206.00K -0.154x -778.86%
2024-05-31 $11.31 Million $257.00K 0.023x +108.83%
2023-05-31 $87.82 Million $-22.59 Million -0.257x -13.81%
2022-05-31 $107.94 Million $-24.40 Million -0.226x -378.28%
2021-05-31 $202.78 Million $16.47 Million 0.081x +210.12%
2020-05-31 $231.04 Million $-17.04 Million -0.074x -224.38%
2019-05-31 $270.14 Million $16.02 Million 0.059x -24.28%
2018-05-31 $252.56 Million $19.78 Million 0.078x -39.08%
2017-05-31 $228.15 Million $29.33 Million 0.129x +25.30%
2016-05-31 $212.35 Million $21.78 Million 0.103x -13.67%
2015-05-31 $220.11 Million $26.16 Million 0.119x +15.62%
2014-05-31 $204.76 Million $21.05 Million 0.103x -12.66%
2013-05-31 $180.41 Million $21.23 Million 0.118x -19.60%
2012-05-31 $151.56 Million $22.18 Million 0.146x +39.31%
2011-05-31 $137.73 Million $14.47 Million 0.105x +85.99%
2010-05-31 $132.47 Million $7.48 Million 0.056x -23.85%
2009-05-31 $127.20 Million $9.44 Million 0.074x -50.88%
2008-05-31 $116.02 Million $17.52 Million 0.151x +920.78%
2007-05-31 $112.07 Million $-2.06 Million -0.018x -114.70%
2006-05-31 $86.82 Million $10.87 Million 0.125x -29.48%
2005-05-31 $73.53 Million $13.05 Million 0.177x +41.16%
2004-05-31 $63.10 Million $7.93 Million 0.126x +7262.63%
2002-05-31 $57.54 Million $-101.00K -0.002x +98.82%
2001-05-31 $50.87 Million $-7.57 Million -0.149x -269.33%
2000-05-31 $57.00 Million $5.01 Million 0.088x +177.61%
1999-05-31 $31.80 Million $-3.60 Million -0.113x -12.21%
1998-05-31 $33.70 Million $-3.40 Million -0.101x +34.70%
1997-05-31 $35.60 Million $-5.50 Million -0.154x -57.07%
1996-05-31 $36.60 Million $-3.60 Million -0.098x --

About Lifecore Biomedical Inc.

NASDAQ:LFCR USA Drug Manufacturers - Specialty & Generic
Market Cap
$165.79 Million
Market Cap Rank
#17204 Global
#4029 in USA
Share Price
$4.42
Change (1 day)
+1.38%
52-Week Range
$3.66 - $8.82
All Time High
$15.45
About

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device … Read more